| Autor: |
Howell BA; Benjamin A. Howell (benjamin.howell@yale.edu) is an instructor in the section of General Internal Medicine and the SEICHE Center at Yale School of Medicine, in New Haven, Connecticut., Martin RA; Rosemarie A. Martin is an associate professor in the Department of Behavioral and Social Sciences, Brown University School of Public Health, in Providence, Rhode Island., Lebeau R; Rebecca Lebeau is the chief health program evaluator in the Rhode Island Executive Office of Health and Human Services, in Cranston, Rhode Island., Truong AQ; Ashley Q. Truong is a PhD candidate in the Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, in Baltimore, Maryland., Wang EA; Emily A. Wang is an associate professor in the Section of General Internal Medicine, Yale School of Medicine., Rich JD; Josiah D. Rich is a professor of medicine and epidemiology in the Division of Infectious Diseases at Brown University and director and cofounder of the Center for Prisoner Health and Human Rights, the Miriam Hospital, in Providence, Rhode Island., Clarke JG; Jennifer G. Clarke is the medical programs director at the Rhode Island Department of Corrections, in Cranston, Rhode Island. |
| Abstrakt: |
To decrease opioid overdose mortality, prisons and jails in the US are increasingly offering medications for opioid use disorder (OUD) to incarcerated people. It is unknown how receipt of these medications in a correctional setting affects health services use after release. In this article we analyze changes in postrelease health care use after the implementation of a statewide medications for OUD program in the unified jail and prison system of the Rhode Island Department of Corrections. Using Medicaid claims data, we examined individual health care use in the community before and after receipt of medications for OUD while incarcerated. We found that inpatient admissions did not change, emergency department visits decreased, and both nonacute outpatient services and pharmacy claims increased after people received medications for OUD while incarcerated. There was no change in total health care costs paid by Medicaid. Our findings provide evidence that people's use of health care services paid for by Medicaid did not increase after they started medications for OUD in correctional settings. Given the frequent interaction of people with OUD with the criminal justice system, offering evidence-based treatment of OUD in correctional settings is an important opportunity to initiate addiction treatment. |
